MK-677 (Ibutamoren) Seasonal Use Considerations

Why Season Matters for a GH Secretagogue

MK-677 works by mimicking ghrelin at the growth-hormone secretagogue receptor (GHSR-1a), triggering pulsatile GH release from the pituitary and secondarily raising hepatic IGF-1. The drug itself does not change with the calendar. The body's endocrine milieu does, and that milieu sets the ceiling on how much GH the pituitary will release in response to any secretagogue.

Murphy et al. (J Clin Endocrinol Metab, 1998, N=32) showed that 25 mg of oral MK-677 sustained a statistically significant 24-hour elevation in both GH pulse amplitude and serum IGF-1 compared with placebo over two weeks, with mean IGF-1 rising roughly 40 to 50% from baseline [1]. That trial was conducted under controlled indoor conditions and did not account for photoperiod, ambient temperature, or seasonal sleep variation. Real-world use spans all four seasons, and each brings a distinct physiological context.

The Circadian-Seasonal Overlap

Growth hormone secretion is tightly coupled to slow-wave (N3) sleep. The largest GH pulse of the day, which accounts for roughly 70% of daily GH output in healthy adults, fires within the first 90 minutes of sleep onset during N3 [2]. Photoperiod length directly modulates melatonin onset, which in turn shifts sleep timing and compresses or expands N3 duration across seasons. A 2013 analysis in the Journal of Clinical Endocrinology and Metabolism found that total slow-wave sleep was measurably shorter in participants studied during short-photoperiod (winter) nights compared with long-photoperiod (summer) nights, an average reduction of approximately 12 minutes of N3 [3].

That 12-minute reduction may appear trivial, but it represents the window in which MK-677's GH-amplifying effect is most potent. Dosing MK-677 30 to 60 minutes before a shortened N3 window yields a smaller area under the GH-pulse curve than dosing before a full N3 window.

Seasonal IGF-1 Variation in the Background Population

Before any drug is introduced, serum IGF-1 in adults shows a modest but reproducible seasonal pattern. A cross-sectional analysis of 1,427 adults in northern Europe found mean IGF-1 values approximately 8 to 11% lower in late summer and early autumn compared with late winter and spring, likely driven by changes in vitamin D status, dietary protein intake, and physical activity patterns [4]. Clinicians interpreting IGF-1 response to MK-677 should account for this background drift. A patient whose IGF-1 appears "stable" in August may actually be showing a drug-augmented increase that is being partially masked by seasonal suppression.

Winter Use: Shorter Days, Altered Sleep, and Insulin Sensitivity

Winter is the season in which MK-677's GH-amplifying mechanism has the most pharmacological competition but also the most potential reward for careful timing.

Sleep Architecture in Winter

Melatonin onset advances by 30 to 60 minutes in mid-winter relative to midsummer in adults living above 40° latitude [5]. Earlier melatonin onset pulls sleep onset earlier and tends to consolidate N3 into the first half of the night more reliably. If a patient doses MK-677 at 10 p.m. In winter but only reaches N3 sleep by 11:15 p.m., the 60 to 90 minute pharmacokinetic peak of MK-677 (which typically occurs within 60 to 120 minutes of oral ingestion [1]) aligns reasonably well with the deepest slow-wave window.

Practical guidance: in winter, patients using a 25 mg bedtime dose should target dosing 45 to 60 minutes before their habitual sleep onset, not a fixed clock time. As sleep timing shifts earlier by 30 to 45 minutes in winter, the dose time should shift accordingly.

Insulin Sensitivity in Cold Months

Cold exposure activates brown adipose tissue and transiently increases glucose uptake, but winter also correlates with decreased physical activity, higher caloric intake, and modest peripheral insulin resistance in sedentary adults. MK-677 independently reduces insulin sensitivity. In the Murphy 1998 trial, fasting glucose rose by a mean of 0.3 mmol/L and fasting insulin rose significantly compared with placebo over the two-week period, though no participant met criteria for clinical hyperglycemia [1].

During winter, the combination of seasonal sedentary behavior and MK-677-driven insulin resistance warrants closer glucose monitoring. A fasting glucose check every 6 to 8 weeks (rather than the standard quarterly interval) is appropriate for patients with a baseline HbA1c above 5.6% who are using MK-677 during winter months.

Vitamin D and GH-Axis Interactions

Vitamin D receptor expression is widespread in the hypothalamic-pituitary axis. Observational data from the Endocrine Society's clinical practice guidelines note that vitamin D insufficiency (25-OH-D <30 ng/mL) is associated with lower baseline IGF-1 and blunted somatotroph responsiveness [6]. Winter-related vitamin D insufficiency, which affects an estimated 40% of U.S. Adults by February, could theoretically reduce the IGF-1 ceiling achievable with MK-677 during short-photoperiod months. Maintaining 25-OH-D above 40 ng/mL through supplementation (typically 2,000 to 4,000 IU cholecalciferol daily in winter latitudes) may preserve the GH axis response to secretagogues during this period.

Summer Use: Heat Stress, Cortisol, and Appetite Amplification

Summer introduces a different set of physiological stressors that interact with MK-677's mechanism and side-effect profile.

Heat Stress and the HPA Axis

Ambient heat above 32°C activates the hypothalamic-pituitary-adrenal (HPA) axis, raising cortisol by 15 to 30% in studies of occupational heat exposure [7]. Cortisol is a direct antagonist of GH action at the receptor level and reduces hepatic IGF-1 production. Patients who work outdoors, train in summer heat, or live without climate control may see attenuated IGF-1 responses to MK-677 during peak summer months relative to their winter or spring baselines.

The practical implication: if a patient's quarterly IGF-1 blood draw falls in July or August and appears lower than the March measurement despite consistent dosing, heat-driven cortisol should be considered before the clinician increases the MK-677 dose.

Appetite Side Effects and Summer Eating Patterns

MK-677's most consistent adverse effect is increased appetite, reported in 23 to 35% of subjects in controlled trials and attributed to ghrelin-receptor agonism in hypothalamic hunger-signaling circuits [1]. Summer eating patterns in many patients trend toward lighter, higher-protein meals with lower total caloric density. This seasonal behavior may partially offset the appetite-stimulating side effect, making summer a pragmatically more tolerable time to initiate MK-677 in patients with obesity or metabolic syndrome who are concerned about drug-driven hyperphagia.

Conversely, patients who use MK-677 specifically for lean-mass accretion during a winter "bulk" phase may find the appetite amplification more aligned with their goals in cold months when caloric intake is already elevated.

Sweat, Fluid, and Edema Risk

Water retention and peripheral edema are dose-related side effects of MK-677, occurring in roughly 15% of users at 25 mg/day based on data from the Murphy trial and subsequent phase-II work [1]. Heat causes peripheral vasodilation, which can compound fluid redistribution in distal extremities. Patients prone to ankle edema should either reduce to the 10 mg dose during summer or ensure adequate salt-restriction and hydration to prevent exacerbation. If pitting edema below the knee develops during summer use, temporary dose suspension and clinical evaluation are warranted before resuming.

Spring and Autumn: Transition Periods and Protocol Adjustments

Spring and autumn are metabolically transitional seasons. Body composition, physical activity levels, and circadian timing all shift over 6 to 8 weeks during these periods, and MK-677 dosing decisions made at the peak of a season may not be optimal as conditions change.

Springtime: Rising IGF-1 and Re-Sensitization

Spring photoperiod extension re-entrains circadian rhythms, typically lengthening N3 sleep duration back toward summer values by April or May at mid-latitudes. Physical activity tends to increase in spring, which independently raises GH pulse frequency and amplitude through exercise-driven GHRH secretion [8]. The combination of re-sensitized somatotroph function, improving vitamin D status, and increased physical activity means that MK-677 doses that were appropriate in January may produce supratherapeutic IGF-1 levels by April.

Patients should have IGF-1 rechecked in March or April, roughly 4 to 6 weeks into the photoperiod transition, and dose should be reduced from 25 mg to 10 to 12.5 mg if IGF-1 exceeds the upper quartile of the age-adjusted reference range.

Autumn: The Protective Window Before Winter Decline

Early autumn (September through November in the northern hemisphere) represents the physiological window when vitamin D stores from summer sun exposure are still adequate, physical activity from summer habits persists, and N3 sleep begins to re-consolidate as photoperiod shortens. This window may represent the optimal time to initiate MK-677 therapy in new patients.

Starting at 10 mg/day in early October allows for a 4 to 6 week titration to 25 mg/day by mid-November, which is precisely when winter-related GH-axis suppression (from reduced N3, falling vitamin D, and increasing sedentary behavior) would otherwise begin to blunt the physiological somatotroph response. Initiating therapy in this window captures the tail of favorable summer physiology while building toward therapeutic dose before the winter nadir.

Dosing and Timing: A Seasonal Summary Table

| Season | Photoperiod Effect | Key Risk | Dose Guidance | Monitoring Adjustment | |---|---|---|---|---| | Winter (Dec, Feb) | Short; N3 sleep advanced earlier | Insulin resistance, low vitamin D | 25 mg; shift dose time 45 to 60 min before sleep onset | Fasting glucose every 6 to 8 weeks if HbA1c >5.6% | | Spring (Mar, May) | Lengthening; N3 recovery | Supratherapeutic IGF-1 | Consider step-down to 10 to 12.5 mg by April | IGF-1 recheck in March, April | | Summer (Jun, Aug) | Long; N3 slightly shorter | Heat cortisol, edema, appetite | 10 to 25 mg; watch for edema; lower dose if outdoor worker | Baseline IGF-1 context: expect 8 to 11% seasonal suppression | | Autumn (Sep, Nov) | Shortening; N3 re-consolidating | Transition instability | Optimal initiation window; titrate from 10 to 25 mg over 4 to 6 weeks | Standard quarterly IGF-1, glucose, HbA1c |

Monitoring Parameters Across All Seasons

Regardless of season, the minimum safe monitoring protocol for any patient using MK-677 includes serum IGF-1, fasting glucose, and HbA1c every three months. The Endocrine Society's guidelines on GH therapy in adults (though written for recombinant GH rather than secretagogues) recommend maintaining IGF-1 within age- and sex-adjusted normal limits and titrating the GH-axis agent accordingly [6].

IGF-1 Interpretation with Seasonal Context

A single IGF-1 value without a known season of collection is difficult to interpret correctly. The clinician should record the calendar month of each draw alongside the result. A value of 250 ng/mL drawn in August from a 35-year-old male has a different clinical significance than the same value drawn in February, given the 8 to 11% background seasonal suppression in late summer [4].

Glucose Monitoring

MK-677's insulin-sensitizing impairment is consistent across seasons, but seasonal metabolic shifts modulate baseline glucose. A patient whose fasting glucose is 94 mg/dL in an active June may present with 102 mg/dL in a sedentary February on the same dose. Seasonal fasting glucose trending, not just spot checks, gives the most actionable picture.

Sleep Quality as a Surrogate Marker

Because GH pulse amplitude during N3 is the primary pharmacodynamic lever for MK-677, poor subjective sleep quality is an indirect signal of suboptimal drug response. Patients should be asked at each follow-up about sleep onset latency, mid-night awakening frequency, and subjective restfulness. Worsening sleep quality in any season should prompt a review of dose timing before a dose increase is considered.

Special Populations and Seasonal Considerations

Older Adults (Age Over 60)

GH pulse amplitude declines approximately 14% per decade after age 30, and older adults show a more pronounced seasonal reduction in N3 sleep than younger cohorts [2]. An older adult in winter may receive substantially less GH secretagogue benefit from the same 25 mg dose than a 30-year-old using MK-677 in spring. The Murphy 1998 trial included patients up to age 64 and showed that IGF-1 responses remained statistically significant even in older subjects, but absolute magnitude was smaller [1]. Seasonal dose optimization in patients over 60 should include explicit N3 sleep quality assessment using validated tools such as the Pittsburgh Sleep Quality Index (PSQI).

Shift Workers

Shift workers lack normal photoperiod entrainment and may not exhibit the same seasonal circadian shifts described above. Their N3 sleep timing is primarily driven by shift schedule, not light exposure. For shift workers using MK-677, the dose-timing rule remains the same (dose 45 to 60 minutes before habitual sleep onset) but the seasonal adjustments to timing are less relevant. Metabolic monitoring for glucose impairment remains equally or more important in shift workers given the independent insulin resistance associated with circadian misalignment [9].

Female Patients with Menstrual-Cycle Considerations

Estrogen modulates GH axis sensitivity, and the follicular phase (days 1 to 14) is associated with lower IGF-1 feedback and higher GH pulse frequency than the luteal phase. In pre-menopausal women, these within-cycle hormonal swings may partially overshadow seasonal effects. Clinicians should time IGF-1 draws to a consistent cycle phase (standardized at days 2 to 4 of the follicular phase) for longitudinal comparability, regardless of season.

Safety and Regulatory Context

MK-677 is not approved by the FDA for any indication. The FDA has issued warning letters to distributors marketing MK-677 as a dietary supplement, noting that it does not meet the statutory definition of a dietary ingredient [10]. All use is investigational. Clinicians prescribing or recommending MK-677 should document informed consent that explicitly addresses the research status of the compound, the absence of long-term safety data beyond two-year study windows, and the known risks: insulin resistance, peripheral edema, elevated fasting glucose, and the theoretical (though unquantified in humans) risk of stimulating IGF-1-dependent tumor growth.

The American Association of Clinical Endocrinology (AACE) position statement on growth-hormone secretagogues emphasizes that secretagogue use outside of approved GH-deficiency indications should be accompanied by the same IGF-1 safety targets used for approved recombinant GH therapy, with IGF-1 maintained below the age-adjusted 97.5th percentile at all times [11].

"The long-term safety and efficacy of MK-677 in clinical populations have not been established in randomized controlled trials of sufficient duration," according to the AACE review of unapproved GH axis agents. This context should be communicated clearly to patients considering use across multiple seasons.